Form 4: ATAI Life Sciences Director Scott Braunstein Granted 103,000 Stock Options

ATAI Life Sciences N.V. Director Scott Braunstein was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026, and expiring in 2035.

Summary

• Scott Braunstein, a Director of ATAI Life Sciences N.V., acquired 103,000 stock options.
• The stock options have an exercise price of $2.25 per share.
• These options will vest on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.
• The options are exercisable from June 26, 2025, and will expire on June 26, 2035.
• Following this transaction, Mr. Braunstein beneficially owns 103,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with the company's long-term performance, generally viewed as a neutral to slightly positive development for corporate governance and incentive alignment.

Positives

• The grant of 103,000 stock options to Director Scott Braunstein aligns his interests with shareholder value and incentivizes long-term performance.

Future Outlook

This document is a historical transaction report and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industry, aiming to incentivize long-term performance and align management interests with shareholder value. This type of compensation is a common component of executive and director remuneration packages across the sector.

Comparison to Industry Standards

• The grant of 103,000 stock options to a director is a common form of equity compensation in the life sciences sector, comparable to practices at similar-stage biotech companies, though specific grant sizes vary widely based on company size, performance, and individual roles.

Related Party Transactions

• Grant of 103,000 stock options to Scott Braunstein, a Director of ATAI Life Sciences N.V., as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price increases.

Next Steps

• Vesting of the 103,000 stock options on the earlier of the day before ATAI Life Sciences N.V.'s next annual meeting or June 26, 2026.
• Potential exercise of the stock options by Scott Braunstein at the exercise price of $2.25 per share, anytime between vesting and the expiration date of June 26, 2035.

Key Dates

Keywords

ATAI Life Sciences, ATAI, Scott Braunstein, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation